At the age of 47, cervical cancer vaccine is generally not available again because the age of termination of cervical cancer vaccine, whether domestic or imported, is 45 years old, and the relative role of cervical cancer vaccine is not significant at the age of 47. At present, the vaccines used to prevent cervical cancer include the nine-valent vaccine, which is suitable for women aged 16-26 years old, mainly for HPV subtypes 6, 11, 16, 18, 31, 33, 45, 52 and 58 infections, with three shots of preventive vaccination; the bivalent vaccine is suitable for women aged 9-25 years old, with HPV subtypes 16 and 18 infections; the quadrivalent vaccine is suitable for The quadrivalent vaccine is suitable for women aged 20-45 years old, and it mainly prevents the infection of HPV subtypes 6, 11, 16 and 18.